Last reviewed · How we verify

Lignocaine

University of Malaya · FDA-approved active Small molecule Quality 19/100

At a glance

Generic nameLignocaine
Also known asIntravenous lignocaine, xylocaine, 2% lignocaine 1 ml, Lidocaine, Lignocaine infusion
SponsorUniversity of Malaya
Target5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results